These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31140614)

  • 1. Fusion with an albumin-binding domain improves pharmacokinetics of an αvβ3-integrin binding fibronectin scaffold protein.
    Gapizov SS; Petrovskaya LE; Shingarova LN; Kryukova EA; Boldyreva EF; Lukashev EP; Yakimov SA; Svirshchevskaya EV; Dolgikh DA; Kirpichnikov MP
    Biotechnol Appl Biochem; 2019 Jul; 66(4):617-625. PubMed ID: 31140614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
    Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
    Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
    Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
    J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin-binding domain extends half-life of glucagon-like peptide-1.
    Tan H; Su W; Zhang W; Zhang J; Sattler M; Zou P
    Eur J Pharmacol; 2021 Jan; 890():173650. PubMed ID: 33049303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tandem fusion of albumin-binding domains promoted soluble expression and stability of recombinant trichosanthin in vitro and in vivo.
    Ren Z; Zhao J; Cao X; Wang F
    Protein Expr Purif; 2022 Dec; 200():106147. PubMed ID: 35917982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins.
    Cantante C; Lourenço S; Morais M; Leandro J; Gano L; Silva N; Leandro P; Serrano M; Henriques AO; Andre A; Cunha-Santos C; Fontes C; Correia JDG; Aires-da-Silva F; Goncalves J
    J Biotechnol; 2017 Jul; 253():23-33. PubMed ID: 28549690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human alphavbeta3 integrin.
    Richards J; Miller M; Abend J; Koide A; Koide S; Dewhurst S
    J Mol Biol; 2003 Mar; 326(5):1475-88. PubMed ID: 12595259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation.
    Wang C; Zhang C; Li Z; Yin S; Wang Q; Guo F; Zhang Y; Yu R; Liu Y; Su Z
    Biomacromolecules; 2018 Mar; 19(3):773-781. PubMed ID: 29328653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains.
    Siegemund M; Oak P; Hansbauer EM; Allersdorfer A; Utschick K; Winter A; Grasmüller C; Galler G; Mayer JP; Weiche B; Prassler J; Kontermann RE; Rothe C
    Front Pharmacol; 2021; 12():759337. PubMed ID: 34759826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G.
    Stork R; Müller D; Kontermann RE
    Protein Eng Des Sel; 2007 Nov; 20(11):569-76. PubMed ID: 17982179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification and characterization of a long-acting ciliary neurotrophic factor via genetically fused with an albumin-binding domain.
    Xu L; Zhang C; Liu L; Zhang Y; Wang Q; Wang J; Liu Y; Su Z
    Protein Expr Purif; 2017 Nov; 139():14-20. PubMed ID: 28711730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibronectin type III domain based monobody with high avidity.
    Duan J; Wu J; Valencia CA; Liu R
    Biochemistry; 2007 Nov; 46(44):12656-64. PubMed ID: 17929945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving pharmacological activities of thrombopoietin mimetic peptide by genetic fusion to albumin-binding domain.
    Li D; Gao G; Zhu B; Ying J
    Biotechnol Lett; 2023 Apr; 45(4):439-448. PubMed ID: 36879168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain.
    Zhang Q; Qian M; Wu Y; Wang Y; Shangguan W; Lu J; Zhao W; Feng J
    Eur J Pharmacol; 2021 Aug; 904():174152. PubMed ID: 33964292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation mechanisms of αVβ3 integrin by binding to fibronectin: A computational study.
    Wang L; Pan D; Yan Q; Song Y
    Protein Sci; 2017 Jun; 26(6):1124-1137. PubMed ID: 28340512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small Bispecific Affinity Proteins for Simultaneous Target Binding and Albumin-Associated Half-Life Extension.
    von Witting E; Lindbo S; Lundqvist M; Möller M; Wisniewski A; Kanje S; Rockberg J; Tegel H; Åstrand M; Uhlén M; Hober S
    Mol Pharm; 2021 Jan; 18(1):328-337. PubMed ID: 33259222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Biodistribution and Extended Serum Half-Life of a Bacteriophage Endolysin by Albumin Binding Domain Fusion.
    Seijsing J; Sobieraj AM; Keller N; Shen Y; Zinkernagel AS; Loessner MJ; Schmelcher M
    Front Microbiol; 2018; 9():2927. PubMed ID: 30538696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fusion of an albumin-binding domain extends the half-life of immunotoxins.
    Guo R; Guo W; Cao L; Liu H; Liu J; Xu H; Huang W; Wang F; Hong Z
    Int J Pharm; 2016 Sep; 511(1):538-549. PubMed ID: 27457423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Serum Albumin and HER2-Binding Affibody Fusion Proteins for Targeted Delivery of Fatty Acid-Modified Molecules and Therapy.
    Dong D; Xia G; Li Z; Li Z
    Mol Pharm; 2016 Oct; 13(10):3370-3380. PubMed ID: 27546214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.